Medicare coverage of PET for cervical cancer

Journal of the American College of Radiology

Volumn 3, Issue 1, 2006, Pages 19-22

  Carey, Brian P ^a   Coleman, R Edward ^b   Grigsby, Perry W ^c   Siegel, Barry A ^c,d  

^a LLP   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Centers for Medicare and Medicaid Services; Insurance coverage; Positron emission tomography; Uterine neoplasms

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; IMAGING SYSTEM; MEDICAID; MEDICARE; METASTASIS; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCIENTIFIC LITERATURE; UTERINE CERVIX CANCER;

EID: 29944439738     PISSN: 15461440     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacr.2005.08.018     Document Type: Article

References (18)

1. E.M. Rohren, T.G. Turkington, R.E. Coleman Clinical applications of PET in oncology Radiology 231 2004 305 332
2. 65 Fed Reg 12999 (March 10, 2000).
3. 42 USC § 1395y(a)(1)(A).
4. Centers for Medicare and Medicaid Services. National coverage decision for PET scans (220.6). Available at: http://www.cms.hhs.gov/mcd/viewncd.asp? ncd_id=220.6&ncd_version=3&basket=ncd%3A220%2E6%3A3%3APET+Scans. Accessed June 28, 2005.
5. P.W. Grigsby, B.A. Siegel, F. Dehdashti Lymph node staging by positron emission tomography in patients with carcinoma of the cervix J Clin Oncol 19 2001 3745 3749
6. P.W. Grigsby, B.A. Siegel, F. Dehdashti, D.A. Mutch Posttherapy surveillance monitoring of cervical cancer by FDG-PET Int J Radiat Oncol Biol Phys 55 2003 907 913
7. A. Singh, P.W. Grigsby, F. Dehdashti, T. Herzog, B.A. Siegel FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma Int J Radiat Oncol Biol Phys 56 2003 489 493
8. B.N. Tran, P.W. Grigsby, F. Dehdashti, T.J. Herzog, B.A. Siegel Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix Gynecol Oncol 90 2003 572 576
9. Agency for Healthcare Research and Quality. Positron emission testing for 6 cancers (brain, cervical, small cell lung, ovarian, pancreatic and testicular). Available at: http://www.cms.hhs.gov/mcd/viewtechassess.asp?id=92. Accessed June 28, 2005.
10. Centers for Medicare and Medicaid Services. Proposed decision memo for positron emission tomography (FDG) for brain, cervical, ovarian, pancreatic, small cell lung, and testicular cancers. Available at: http://www.cms.hhs.gov/ mcd/viewdraftdecisionmemo.asp?id=92. Accessed June 28, 2005.
11. http://www.cms.hhs.gov/media/press/release.asp?Counter=1337. Accessed June 28, 2005.
12. 18F-FDG PET on managing patients with colorectal cancer the referring physician's perspective J Nucl Med 42 2001 586 590
13. R. Tucker, M. Coel, J. Ko, P. Morris, G. Druger, P. McGuigan Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management first year's experience in a clinical center J Clin Oncol 19 2001 2504 2508
14. 18F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma J Nucl Med 42 2001 1139 1143
15. 18F-FDG PET on staging and managing patients with breast cancer the referring physician's perspective J Nucl Med 42 2001 1334 1337
16. M.A. Seltzer, C.S. Yap, D.H. Silverman The impact of PET on the management of lung cancer the referring physician's perspective J Nucl Med 43 2002 752 756
17. D. Gopalan, D. Griffiths, C. Townsend Fluorodeoxyglucose positron emission tomography in clinical oncology the referrer's perspective Nucl Med Comm 23 2002 1046-6
18. B.E. Hillner, R. Tunuguntla, M. Fratkin Clinical decisions associated with positron emission tomography in a prospective cohort of patients with suspected or known cancer at one US center J Clin Oncol 22 2004 4147 4156